视网膜中央静脉阻塞继发黄斑水肿的治疗进展——从临床试验到临床实践  

The advance in treatment of macular edema secondary to central retinal vein occlusion——from clinical trial to clinical practice

作　　者：张永鹏[1] 彭晓燕[1] 

机构地区：[1]首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科学与视觉科学重点实验室,100730

出　　处：《眼科》2012年第4期222-227,共6页Ophthalmology in China

摘　　要：视网膜中央静脉阻塞(CRVO)是常见的威胁视力的视网膜血管疾病,其病因复杂,临床上针对其并发症黄斑水肿的治疗亦较为棘手。近年来,有较多CRVO治疗的新探索。在药物治疗方面,有抗血管内皮生长因子(VEGF)药物包括Beva-cizumab、Ranibizumab、Pegaptanib和VEGF Trap-Eye,曲安奈德和玻璃体内植入药物缓释系统如醋酸氟轻松(Retisert)和地塞米松(Ozurdex)。在激光和手术治疗效果方面也有一些探索。目前仍有一些大型多中心随机临床研究正在进行中。尽管已有循征医学证据验证了某些疗法的有效性和安全性,但从临床试验到临床实践,仍有相当多的具体问题需要解决。Central retinal vein occlusion （CRVO） is a common, sight-threatening retinal vascular disorders. The etiology of CRVO is complicated and current treatments for CRVO and its sequelae such as macular edema are still tough. However, there are many e- merging treatments in recently years. Intravitreal pharmacologic agents which include anti-vascular endothelial growth factor （Beva- cizumab, Ranibizumab, Pegaptanib, and VEGF Trap-Eye）, triamcinolone acetonide and sustained delivery corticosteroid device （fluoci- nolone acetonide and dexamethasone） are promising. There are also some researches on the efficiency of laser and surgery. Several large, well-designed, prospective, randomized controlled trials are still ongoing worldwidely. Although the efficiency and safety of some treatments have been proved by evidence-based medicine, there are still lots of questions which should be answered on the way from clinical trial to clinical practice. （Ophthalmol CHN, 2012, 21： 222-227）

关 键 词：视网膜中央静脉阻塞 黄斑水肿/治疗 临床试验 循征医学 

分 类 号：R774[医药卫生—眼科]